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INTRODUCTION
Rotavirus can lead to severe life-threatening gastro-
enteritis in infants and young children worldwide. 
Unlike many other enteropathogens, rotavirus af-
fects children in both developed and developing 
countries (1-2) and is not associated with socio-
economic factors. However, the risk of dying from 
severe rotavirus-associated infection is higher in 
lower-income countries due to various factors, in-
cluding limited access to healthcare facilities, mal-
nutrition, earlier onset of infection, and mixed in-
fections involving rotavirus and other pathogens. 
Rotavirus infects most children by three years of 
age, and prevention of rotavirus spread is virtually 
impossible, even in environments with the highest 
hygiene measures (2). Improvements in the avail-
ability of safe water and sanitation, access to oral 
rehydration therapy, and higher vaccine coverage 
have reduced the overall burden of gastroenteritis 
in children (3-4). From 1980 to 2002, Brazil showed 
a decrease by 91.5% in mortality due to gastroen-
teritis among children aged less than five years (3-4). 
During the same period, the proportion of infant 
deaths attributed to gastroenteritis fell from 41% to 
4.7%, but with a range of 2.1% in the South-
east region to 7.8% in the Northeast (3-4). Infant 
mortality decreased from 85.2 per 1,000 children in 
1980 to 25.1 per 1,000 children in 2002 (3-4). 
Two surveys conducted in São Paulo in 1984-1985 
and 1995-1996, including representative samples 
of the population aged 0-59 month(s), reported an 
overall reduction in the point prevalence of gas-
troenteritis from 1.7% to 0.9%, and a reduction in 
hospitalization due to gastroenteritis from 2.21 to 
0.79 per 100 children-years (5). The latest survey 
(1995-1996) reported a 4.7% period prevalence of 
gastroenteritis when inquired about diarrhoea dur-
ing the last two weeks (5). In contrast, a third sur-
vey carried out in the metropolitan area of Recife 
(Northeast region) in 1997 reported a 5.6% point 
prevalence of gastroenteritis and a period preva-
lence of 16.9% when inquired about diarrhoea dur-
ing the last two weeks (6).
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Despite improvements in health conditions among 
Brazilian children aged less than five years, gastro-
enteritis remains a significant burden in children 
in this age-group. In 2002, gastroenteritis caused 
about 3,000 deaths across the country, representing 
a rate of 19.6 deaths per 100,000 children aged less 
than five years, with a range of 34.2-7.6 deaths per 
100,000 children in the Northeast and the South-
east respectively. Of the total deaths in children 
aged less than five years, infants were the most 
vulnerable group, with 81.8% of all deaths due to 
gastroenteritis (7).
Several studies have focused on the occurrence of 
acute diarrhoea associated with outpatient clinic 
visits and hospitalizations, yielding average preva-
lence rates that ranged from 12% to 42% through-
out the country (8). An official nationwide surveil-
lance system has been implemented through the 
Brazilian Health Ministry to determine the overall 
burden of rotavirus-associated disease and to moni-
tor strain diversity. In March 2006, the Brazilian 
Health Ministry made available an attenuated vac-
cine against rotavirus-associated gastroenteritis for 
universal use in the country.
In this paper, we report the burden of disease and 
costs of gastroenteritis due to rotavirus in Brazil-
ian children and the expected cost-effectiveness of 
a national rotavirus vaccination programme. The 
results presented here are based on a major study 
conducted in the region (9-10). Country-level esti-
mates were used in the present analysis, and find-
ings differ from the earlier study. In addition, this 
paper considers information on the recent intro-
duction of the vaccine in the public sector in Brazil, 
including its cost.
MATERIALS AND METHODS
Model overview 
A model was developed to estimate the disease out-
comes and costs associated with gastroenteritis due 
to rotavirus in a hypothetical annual birth-cohort 
of children for a five-year period. The performance 
of the vaccination strategy is described using in-
cremental cost-effectiveness ratios, defined as the 
additional cost of a specific strategy, divided by its 
additional benefit, compared with the next most 
costly strategy. Results are presented in US dollar 
(as in 2003) for local and regional decision-makers. 
Future costs and disability-adjusted life-year (DALY) 
estimates were discounted at an annual 3% rate as 
recommended by the US Panel of Cost-effectiveness 
in Health and Medicine (11) and the World Bank 
Global Burden of Disease Project (12). Model out-
comes included averted hospitalizations, outpatient 
visits, deaths and DALYs, and costs. Costs, such as 
non-medical direct costs (transportation costs) or 
productivity losses to caregivers, were not included 
in the cost-effectiveness calculations; however, they 
were presented in the cost calculations. 
The annual birth-cohort considered in the model 
included 3,471,000 children aged less than five 
years (13). The age distribution of rotavirus-associ-
ated disease was estimated for each of the disease 
outcomes using published findings of studies from 
Brazil and the Latin American region (14-23). 
Rotavirus-associated disease and economic 
burden
The burden of disease was estimated as the ex-
pected number of rotavirus-associated events (hos-
pitalizations, outpatient visits, and deaths) during 
the first five years of life for a single birth-cohort. 
The risk of rotavirus-associated events were based 
on the cumulative risk of each event due to acute 
gastroenteritis during the first five years of life and 
the proportion of these events attributed to rotavi-
rus. Detailed explanation of the methods used for 
estimating the burden of disease in Brazil can be 
found elsewhere (10).
In addition to estimating numbers of hospitaliza-
tions, outpatient visits and deaths, the burden of 
disease was also expressed in terms of DALYs (12). 
DALYs provide a standardized measure of the bur-
den of disease that allows for cross-comparisons of 
the burden of disease and comparison with other 
diseases. The DALY estimate included years of life 
lost due to premature mortality and years lived 
with disability. The DALY loss from mortality was 
calculated based on the average country-specific life 
expectancy at zero and one year of age using life 
tables reported by the World Health Organization 
(WHO) (24). The average life expectancy for males 
and females is 68.2 at birth and 69.7 at one year of 
age. For the calculation of years lived with disability, 
only morbidity from disease severe enough to re-
quire medical care was considered. Default disabil-
ity weights from the Global Burden of Disease Study 
(12), the WHO guidelines for cost-effectiveness 
studies (25), and estimated rotavirus illness duration 
of six days (26) were used in calculating years lived 
with disability. DALYs calculated reflect the disabili-
ty weight and duration estimates for gastroenteritis 
due to rotavirus as provided in the Global Burden of 
Disease Study (12). This calculation is age-weighted 
(25) and uses an annual discount rate of 3%. Constenla DO et al. Economics of rotavirus vaccine in Brazil
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The economic burden of rotavirus-associated gas-
troenteritis for Brazil was estimated by combining 
estimates of the number of each type of event with 
information on the costs associated with the event. 
Country-specific estimates of healthcare costs were 
developed for hospital and outpatient rotavirus-
associated events. In addition to healthcare costs, 
transportation costs to healthcare facilities were 
also included in the calculations of costs. For the 
base case analysis, these costs were based on as-
sumptions made about the number of trips to and 
from the doctor’s office and/or the hospital and 
the cost of each trip. The number of trips to and 
from the doctor’s office and/or hospital was based 
on the amount of outpatient visits and hospital 
admissions reported by physicians in a multicentre 
hospital-based rotavirus surveillance study (Abate 
H, Linhares AC, Venegas G, Vergara R, Lopez, P, 
Jimenez E et al. Results of a hospital-based study 
of rotavirus gastroenteritis in Latin American chil-
dren. Resumen presentado en el Congreso Interna-
cional de Pediatría en Cancún, México, 15-20 de 
agosto de 2004. Unpublished) conducted in Belem. 
These estimates were considered to be the most re-
liable estimates for Brazil. Indirect costs associated 
with lost time from paid work were also calculated. 
For the base case analysis, these costs were based 
on the number of days off from work (one outpa-
tient consultation or one day in the hospital was 
assumed to be the same as one day off from work), 
assuming an average 2003 minimum monthly sala- 
ry in Brazil and 22 days off from work. A complete 
description of the methods used in calculating the 
economic burden was reported elsewhere (10). 
Effectiveness of vaccination and costs
Estimates of the effectiveness of rotavirus vaccina-
tion were based on the results of clinical trials 
of human rotavirus vaccine administered orally 
to infants at two and four months of age (27-28). 
The vaccine demonstrated an 85% efficacy in pre-
venting hospitalizations for gastroenteritis due to 
rotavirus (27). Efficacy in averting deaths was as-
sumed to be the same as that for hospitalized cases 
(85%). No data on specific efficacy are available for 
outpatient visits. Therefore, rates for the episodes 
of severe gastroenteritis due to rotavirus were con-
sidered (84.7-86%) to be rotavirus-associated gas-
troenteritis (27-28). For the baseline analysis, the 
efficacy of one dose was assumed to be 62.5% [95% 
confidence interval [CI] (16-83) (López P, Linhares 
AC, Pérez-Schael I, Ruiz-Palacios GM, Costa-Clem-
ens SA, Sanchez N et al. Early protection against se-
vere rotavirus gastroenteritis—RIX4414 experience 
in Latin America. European Society of Paed Infect 
Dis Congress, May 3-5 2003, Basel, Switzerland. 
Unpublished). It was further assumed that efficacy 
would not decline in the second year (Linhares. 
Personal communication, 2007) and subsequent 
years following vaccination.  
We assumed that children would receive the vac-
cine to prevent rotavirus-associated gastroenteritis 
at the time of the diphtheria-tetanus-pertussis-
hepatitis B virus-Haemophilus influenzae vaccine 
(DTPwHBV/Hib) and the oral polio virus vac-
cine (OPV) in Brazil, which are given at two, four, 
and six months of age. In the baseline analysis, the 
national coverage of the third dose of DTPw at one 
year of age for 2003 was estimated to be 96% (29). 
Rotavirus vaccination would occur with DTPwH-
BV/Hib and OPV doses (one and two); however, 
standardized data are only available for the cover-
age of the third dose. 
In this analysis, we included the cost of adminis-
tration of the vaccine, the price of each dose, the 
number of doses given (based on coverage level), 
and expected losses from waste (10%). The costs 
for administering the vaccine included the cost 
of healthcare personnel and training, cold-chain, 
storage space, and public education. Brazil has the 
necessary infrastructu  re for running a national ro-
tavirus vaccination programme, based on its ex-
tensive history of administering oral polio vaccine. 
Therefore, the incremental administration costs 
are assumed to be low. A few studies estimated the 
cost of immunization for current EPI vaccines (30-
33); however, no data on the incremental cost of 
adding a vaccine to the current EPI regimen were 
found. Based on the range of estimates found in 
studies conducted on the immunization cost and 
the assumption of low incremental costs, the mod-
el assumes the cost for administering the vaccine as 
US$ 0.50 per dose. The Brazilian Ministry of Health 
purchased the vaccine at a cost of US$ 7-8 per dose 
and made it available for the public sector in March 
2006.
Table 1 summarizes the best estimates used in the 
analysis.
Sensitivity analyses
One-way sensitivity analyses were done by calculat-
ing the main outcomes, the economic burden, and 
cost-effectiveness, for different scenarios that are 
likely to influence the costs of rotavirus-associated 
disease and the cost-effectiveness of a vaccination 
programme. These scenarios included: high and Constenla DO et al. Economics of rotavirus vaccine in Brazil
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low end-estimates of outpatient visits, hospitaliza-
tion and mortality rates, vaccine efficacy against 
hospitalizations and death, hospital per diem, cost 
of outpatient visit, and price of vaccine. 
RESULTS
Burden of disease 
Table 2 shows the projected disease outcomes of 
rotavirus in Brazil under current treatment (no 
vaccination) and with rotavirus vaccination. By the 
age of five years, one in five (205 per 1,000) chil-
dren required a clinic visit for rotavirus-associated 
gastroenteritis, one in 29 (35 per 1,000) children 
was hospitalized for gastroenteritis due to rotavirus, 
and one in 1,429 (0.7 per 1,000) children died 
due to rotavirus-associated gastroenteritis. An es-
timated 24 DALYs per 1,000 births were lost from 
these outcomes. This compares with the rates ob-
served in other countries in the region where rates 
of rotavirus-associated mortality are low (34-35). 
For the base case, the model predicts that a total of 
550,198 outpatient-visits (159 per 1,000), 91,127 
hospitalizations (26 per 1,000), and 1,804 deaths 
Table 1. Input variables for a cost-effectiveness analysis of a rotavirus vaccination programme in Brazil
Variable Baseline estimate Source of data
Demographics
   Birth-cohort 3,471,000 PAHO, 2004 (13)
   Life expectancy at birth (years)
     Male 
     Female
68. 2 
69.7
WHOSIS, 2000 (24)
Cumulative risk of events for rotavirus- 
   associated gastroenteritis per 1,000 (<5 years)
     Hospitalization rate 35
     Ambulatory visit rate 199.5 Rheingans et al., 2006 (10)
     Mortality rate 0.7 Rheingans et al., 2006 (10)
Direct medical cost of rotavirus-associated 
   gastroenteritis per patient (US$)*
     Hospitalized cases
     Ambulatory cases
150.97
10.81
Rheingans et al., 2006 (10)
Non-medical direct costs (transport) (US$)
     Hospitalized cases
     Ambulatory cases
1.49
0.04
Rheingans et al., 2006 (10)
Indirect costs
     Hospitalized cases
     Ambulatory cases
18.58
8.35
Rheingans et al., 2006 (10)
Vaccine
   Coverage 96% WHO-UNICEF best estimates, 2003 (29)
   Efficacy (outpatient visits due to 
     rotavirus) 85%
Ruiz-Palacios et al., 2006 (27)  
Salinas et al., 2005 (28)
   Efficacy (hospitalizations due to 
     rotavirus)
85% Ruiz-Palacios et al., 2006 (27)
   Efficacy (death due to rotavirus) 85% Assumes efficacy is same as for 
hospitalizations (27)
   Administration cost (US$ per dose) 0.50 Author’s assumption
   Vaccine price (US$ per dose) 7-8 Brazilian Ministry of Health, 2006 
(purchase price)
*These costs include the direct medical costs of hospitalization, outpatient visits, diagnostic tests, and 
medication; PAHO=Pan-American Health Organization; UNICEF=United Nations Children’s Fund; 
WHOSIS=World Health Organization Statistical Information SystemConstenla DO et al. Economics of rotavirus vaccine in Brazil
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(0.52 per 1,000) associated with gastroenteritis due 
to rotavirus would be prevented by rotavirus vac-
cination. This represents an overall reduction of 
77%, 76%, and 73% respectively. 
Costs of events due to rotavirus-associated 
gastroenteritis 
Estimates of the direct medical costs, direct non-
medical costs, and indirect costs for inpatients and 
outpatients with gastroenteritis are provided in 
Table 3 and are based on the hospital-based surveil-
lance. The total direct medical cost for inpatients 
was US$ 150.97, with 86% of the cost attributed to 
the hospital stay and the remainder due to the cost 
of diagnostics and medication. For outpatients, the 
total direct medical cost was only US$ 10.81, of 
which 50% is attributed to the cost of the visit. 
Forty-four percent of caregivers reported that they 
paid to visit the child at the hospital. For all caregiv-
ers (including those who did not report payment per 
visit), the mean cost to transport child to the hospital 
was US$ 1.49. This was multiplied by the mean num-
ber of trips (8.58) for a total of US$ 12.78 per child. 
For outpatients, 6% of caregivers reported that they 
paid to visit the child at the outpatient clinic. Of those 
who paid, the median cost to transport the child was 
US$ 0.04. This was multiplied by the mean number 
of trips (0.5) for a total of US$ 0.02 per child. 
Table 2. Estimated burden of rotavirus in Brazil 
 with and without vaccination programme
 Type of event
Total 
events
Events per 
1,000 children
 Current management 
   (without vaccination)
     Hospitalizations  120,513 34.72
     Outpatient visits 712,249 205.20
     Deaths 2,475 0.71
     DALYs* 83,365 24.02
 With vaccination
   Hospitalizations  29,386 8.47
   Outpatient visits 162,051 46.69
   Deaths 671 0.19
   DALYs* 22,671 6.53
 Benefit of vaccination 
   (averted events)†
     Hospitalizations  91,127 26.25
     Outpatient visits 550,198 158.51
     Deaths 1,804 0.52
     DALYs* 60,694 17.49
*Discounted at 3%; †Benefit of vaccination is 
based on the vaccine effectiveness, which incor-
porates information on the vaccine efficacy and 
coverage; DALYs=Disability-adjusted life-years
Table 3. Costs of treating gastroenteritis in Brazil estimated from hospital-based surveillance data*
Variable
Inpatients (n=43)† Outpatients (n=52)†
   Mean Range Mean Range
Cost per stay/visit (US$) 129.76 35.07-280.56  5.39
Medications (US$) 14.47 1.64-62.25  4.87  0.22-33.98
Diagnostics (US$) 6.74‡  0-14.97  0.55  0-12.50
Total direct medical costs (US$) 150.97‡ 36.71-357.78 10.81  0.22-46.48
Percentage who paid to visit child 44 6
Payment to visit child (US$) 1.49‡ 0-8.77 0.04‡  0-1.30
Mean number of trips 8.58 0-48 0.5 0-6 
Non-medical direct costs (US$) 
  (transport) 
12.78‡ 0-1,161 0.02‡ 0-31.50
Percentage who lost time from work 53 48
Hours lost from work 28.90¶ 5-108 19.92¶ 2-120
Average female hourly wage (US$) 1.45§  1.45§
Indirect costs (US$) 41.90  28.88
Total cost per patient (US$) 205.65 39.71
*10 sites participated in the health economic component of the hospital-based surveillance study: 2 secondary-
level hospitals, 5 primary healthcare units (Unidades Basicas de Saude [postos de saude]), 2 private healthcare 
units (emergency rooms linked to tertiary-level hospitals), and one Unidad del Programa de Familia Saludable; 
†Cost data are based on US$ as in 2003; ‡Missing one value; ¶Median value calculated for those parents who 
indicated they lost time from work; §This value assumes an eight-hour shiftConstenla DO et al. Economics of rotavirus vaccine in Brazil
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Table 5. Estimates of costs, net benefits, and 
cost-effectiveness of a rotavirus vac-
cination programme in Brazil
Vaccine programme cost* Amount† (US$)
Vaccine administration 3,332,160
Vaccine (US$ 7-8/dose) 54,980,640
Total cost 58,312,800
Net medical direct cost  39,044,331
Incremental cost-effectiveness 
  ratio
  Cost per DALY  643
  Cost per life saved  21,643
  Cost per hospitalization  
  averted  428
  Cost per medical visit averted  70
*Vaccination cost assumes only the cost of 
vaccinating children who would receive the 
vaccine, based on vaccine coverage estimates 
and 10% wastage; †The intervention cost, net 
medical cost, and incremental cost-effective-
ness ratio (US$/DALY) assume a vaccine price 
of US$ 7-8 per dose. Values are based on US$ as 
in 2003; DALY=Disability-adjusted life-year
Table 4. Estimated healthcare costs* (US$) and 
benefits of a rotavirus vaccination pro-
gramme in Brazil
 Type of event
Direct medi-
cal cost*
Mean cost per 
child*,†
 Current management 
   (without vaccination)
     Hospitalizations   17,813,038 5.13
     Outpatient visits   7,519,460 2.17
     Total   25,332,498 7.30
 With vaccination
   Hospitalizations   4,350,341 1.25
   Outpatient visits   1,713,689 0.49
   Total   6,064,030 1.75
 Benefit of vaccination 
   (averted costs) ‡
     Hospitalizations   13,462,697
     Outpatient visits   5,805,771
     Total   19,268,469
*Values are based on US$ as in 2003; †Calculation 
only includes direct medical costs to the health-
care system; ‡Benefit of vaccination is based on 
the vaccine effectiveness, which incorporates in-
formation on the vaccine efficacy and coverage
The indirect cost associated with lost wages for in-
patients was more than that for outpatients (US$ 
41.9 vs US$ 28.9) because the percentage of sub-
jects who lost time from work was higher for care-
givers of inpatients than outpatients (53% vs 48%) 
and, on average, caregivers of inpatients lost more 
time from work than outpatients (28.9 hours vs 
19.9 hours).
Table 4 shows the estimated healthcare costs per 
birth-cohort from these rotavirus-associated events 
in Brazil. In the absence of vaccination, it is esti-
mated that rotavirus-associated gastroenteritis re-
sults in a total healthcare cost of over US$ 25.3 mil-
lion for each annual birth-cohort in Brazil, which is 
equivalent to US$ 7.30 per child. Seventy percent 
of these costs are associated with hospitalization. 
Vaccination is likely to reduce the economic bur-
den of gastroenteritis due to rotavirus significantly 
in Brazil, averting US$ 19.3 million (76% of the to-
tal healthcare cost). 
age and a basic vaccine price of US$ 7-8 per dose. 
Costs of the vaccination include the cost of the vac-
cine and its administration. Moreover, vaccination 
cost assumes only the cost of vaccinating children 
who would receive the vaccine, based on vaccine 
coverage estimates and 10% wastage. Benefits are 
expressed as net medical costs from the healthcare 
system perspective and the cost-effectiveness ratio. 
All of these cost and benefit measures vary directly 
with the vaccine price.
Cost-effectiveness of a rotavirus vaccination 
programme
The expected costs and benefits of a rotavirus 
vaccination programme in Brazilian children 
are presented in Table 5. Results shown here are 
for a single birth-cohort, assuming 96% cover-
At a price of US$ 7-8 per dose, the net medical cost 
for the healthcare system to vaccinate the Brazilian 
birth-cohort with the rotavirus vaccine would be 
US$ 39 million. From the healthcare perspective, 
a rotavirus vaccination costs US$ 643 per DALY 
averted, US$ 21,643 per life saved, US$ 428 per 
hospitalization averted, and US$ 70 per medical 
visit averted. The vaccination programme would 
be considered cost-saving to the healthcare system 
at a vaccine price lower than US$ 2.17 per dose. 
Higher vaccine prices require a net economical in-
vestment but provide a health benefit. 
Sensitivity analysis
The estimated medical cost per child is most sensi-
tive to changes in assumptions regarding the inci-
dence of hospitalization due to rotavirus and the 
cost of hospital treatment. A 25% change in either Constenla DO et al. Economics of rotavirus vaccine in Brazil
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of those parameters results in a 12-15% change in 
the medical cost per child. The estimates of incre-
mental cost-effectiveness rate are affected by the ro-
tavirus-associated mortality rate, efficacy of vaccine 
against mortality, and vaccine price. A 25% change 
in any of these variables results in 15-40% change 
in the incremental cost-effectiveness ratio. Overall, 
an increase in the incidence of rotavirus and effi-
cacy of vaccine will result in a lower incremental 
cost-effectiveness ratio making a vaccination pro-
gramme more cost-effective. Furthermore, a reduc-
tion in the price of rotavirus vaccination (US$ 5 per 
dose) will yield a lower incremental cost-effective-
ness ratio of US$ 341 per DALY averted, making the 
vaccine even more cost-effective.
DISCUSSION
This is the first time a national rotavirus vaccina-
tion programme is evaluated in Brazil in economic 
terms. Rotavirus-associated gastroenteritis is a com-
mon disease with an estimated 832,762 cases of 
gastroenteritis due to rotavirus and 2,475 deaths 
occurring annually in Brazil. The large burden of 
outpatient visits due to rotavirus-associated gastro-
enteritis is a significant contributor to the substan-
tial costs in the healthcare system. 
Vaccination provides an effective opportunity for 
improving children’s health in Brazil. We estimated 
that vaccination would prevent more than three-
fourths of all cases due to rotavirus-associated gas-
troenteritis, including 1,804 deaths. This translates 
into almost one life saved and 185 cases prevent-
ed per 1,000. We also estimated that vaccination 
would result in total medical savings of US$ 19.3 
million. At the current vaccine price of US$ 7-8 
per dose, vaccination would be cost-effective from 
the perspective of healthcare system based on the 
WHO benchmarks for cost-effectiveness. 
It is important to emphasize that even if vaccina-
tion appears to be cost-effective according to a 
criterion of the cost-effectiveness ratio being less 
than the per-capita GDP of Brazil, it may not be af-
fordable. Even an intervention that provides good 
value for resources invested may have prohibitive 
financial requirements that could not be accom-
modated by the healthcare system of Brazil. 
Limitations of this analysis include, but are not 
limited to, uncertainties around the epidemiology 
of gastroenteritis due to rotavirus in Brazil and effi-
cacy of vaccine against death. Moreover, the actual 
proportion of diarrhoeal deaths due to rotavirus is 
unknown. Efforts should be made to ascertain the 
incidence of deaths due to rotavirus-associated gas-
troenteritis using active surveillance studies, espe-
cially in regions of the country where there may be 
limited access to emergency treatment facilities.
Another limitation is related to the coverage rate 
and/or timing of vaccination. The coverage is based 
on the coverage of other vaccines, e.g. DTPwHBV/
Hib and OPV, which may not be an accurate esti-
mation of coverage for the current rotavirus vac-
cine. In the analysis, we assumed that all groups 
within the country have equal likelihood of vac-
cination, and all children would receive the vaccine 
at the recommended time. If high-risk populations 
were missed or vaccination was delayed, the effec-
tiveness would be reduced. Since rotavirus-associ-
ated gastroenteritis occurs in young children and 
protection is conferred from the time of vaccine 
dose 1 until dose 2 is given (29), it is important that 
the vaccine be given on time; this is the scenario 
adopted in the health economic model used for 
this analysis. Future considerations should be made 
to account for the fact that not all children will re-
ceive the vaccine at the recommended time.
A final limitation is the lack of data on the magni-
tude of herd immunity which may be conferred by 
the partial coverage of vaccination into a popula-
tion. The analysis considered the direct effects of 
vaccination, but it did not consider the indirect 
protective effect on persons never vaccinated. The 
herd immunity effect could be large and might 
offset inefficiencies in the delivery of a complete 
course and vaccination on time to all children. This 
analysis supports the conclusion that gastroenteri-
tis due to rotavirus poses a sizeable burden in Bra-
zil and results in 120,513 hospitalizations, 712,249 
outpatient visits, 2,475 deaths, and 83,365 DALYs 
annually in Brazil. At a price per dose of US$ 7-8 for 
Brazil, the cost per DALY averted is less than US$ 
700. This ratio is less than per-capita GDP of Brazil, 
but more importantly, it compares favourably with 
the ratios of other vaccines (36). For example, the 
cost-effectiveness of pneumococcal conjugate vac-
cination ranged from US$ 110 to US$ 2,150 across 
a range of countries (37-38); rotavirus vaccina-
tion ranged from US$ 290 to US$ 12,300 in Latin 
American countries (9,34-35,39-40); and influenza 
vaccination was cost-saving in high-risk children in 
Argentina (41).  
ACKNOWLEDGEMENTS
Funding  for  the  study  was  provided  by  GlaxoS-
mithKline Biologicals. Full independence of meth-
ods and control over publication remain with the Constenla DO et al. Economics of rotavirus vaccine in Brazil
Volume 26 | Number 4 | December 2008 395
authors along with responsibility for any errors. 
The authors thank the following experts for their 
assistance in identifying epidemiological data and 
their general support for the study: Alfredo Gilio 
(Diretor da Divisaõ de Pediatria, Clínica of Hospi-
tal Universitário, Saõ Paulo); Expedito Luna (Dire-
tor, Departamento de Vigilância Epidemiológica, 
Brasilia); Divina das Dôres de Paula Cardoso and 
Paulo da Costa (Instituto de Patologia Tropical 
e Saúde Pública, Universidade Federal de Goiás, 
Goiânia, Goiás); Marcos Bosi Ferraz (Centro Pau-
lista de Economía da Saúde, Saõ Paulo); and Nilo 
Serpa (Analista de Sistemas, Secretaria de Saúde do 
Estado de Rio de Janeiro). 
REFERENCES
1.  Bresee JS, Glass RI, Ivanoff B, Gentsch JR. Current sta-
tus and future priorities for rotavirus vaccine develop-
ment, evaluation and implementation in developing 
countries. Vaccine 1999;17:2207-22.
2.  Kapikian AZ, Hoshino Y, Chanok RM. R Ves. In: Knipe 
DM, Howley PM, editors. Fields virology, v. 1. 4th ed. 
Philadelphia: Lippincott, 2001:1787-834. 
3.  Victora C, Barros F. Diarrheal disease among children 
under five years in the Americas, 1980-1992. New York, 
NY: United Nations Children’s Fund, 1993. 230 p. 
4.  Brasil. Ministério da Saúde. Departamento de Aná-
lise de Situação de Saúde/SVS. Indicadores de dados 
básicos para a saúde. Brasilia, D.F.: Ministério da 
Saúde, 2004. 280 p. 
5.  Benício MHD e Monteiro CA. Tendência secular da 
doença diarreica na infância nsa cidades de São Paulo 
(1984-1996). Rev Saúde Pública 2000;34(Suppl 6):S83-90.
6.  Instituto Nacional de Alimentação e Nutrição. II pes-
quisa estadual de saúde e nutrição: saúde, nutrição, 
alimentação e condições socioeconômicas no estado 
de pernambuco. Brasilia, D.F.: Ministério da Saúde, 
1998. 189 p.
7.  Brasil. Ministério da Saúde. Departamento de Análise 
de Situação de Saúde/SVS. Sistema de informação so-
bre mortalidade. Brasilia, D.F.: Ministério da Saúde, 
2004. 460 p. 
8.  Linhares AC, Bresee JS. Rotavirus vaccines and vac- Rotavirus vaccines and vac-
cination in Latin America. Rev Panam Salud Publica 
2000;8:305-31.
9.  Rheingans RD, Constenla D, Antil L, Innis BL, 
Breuer T. Potential cost-effectiveness of vaccination 
for rotavirus gastroenteritis in eight Latin American 
and Caribbean countries. Rev Panam Salud Publica 
2007;21:205-16. 
10. Rheingans RD, Constenla D, Antil L, Innis B, Breuer 
T. Economic and health burden of rotavirus gastro- rotavirus gastro-
enteritis for the 2003 birth cohort in eight Latin 
American and Caribbean countries. Rev Panam Salud 
Publica 2007;21:192-204. 
11. Gold MR, Siegel JE, Russell LB, Weinstein MC, edi-
tors. Cost-effectiveness in health and medicine. Ox-
ford: Oxford University Press, 1996. 456 p.
12. Murray CJL, Lopez AD. The global burden of disease: 
a comprehensive assessment of mortality and disabil-
ity from diseases, injuries and risk factors in 1990 and 
projected to 2020. Cambridge: Harvard University 
Press, 1996. 1,022 p.
13. Pan-American Health Organization. Health analysis 
and Information systems area. Regional core health 
data initiative; technical health information system. 
Washington, DC: Pan-American Health Organiza-
tion, 2004. 18 p. (http://www.paho.org/English/SHA/
coredata/tabulator/ newTabulator.htm, accessed on 4   
September 2003). 
14. Barraza P, Avendaño LF, Spencer E, Calderón A, Pren-
zel I, Duarte E. Hospital infection caused by rotavirus-
es in infants, Santiago, Chile. Bol Oficina Sanit Panam 
1986;101:328-38.
15. Bok K, Castagnaro NC, Diaz NE, Borsa A, Cagnoli 
MR, Nates S et al. Rotavirus laboratory network: 
results after one year of observation. Rev Argent Micro-
biol 1999;31:1-12.
16. Bok K, Castagnaro N, Borsa A, Nates S, Espul C, Fay 
O et al. Surveillance for rotavirus in Argentina. J Med 
Virol 2001;65:190-8.
17. Cardoso DDP, Soares CMA, Dias e Souza MB, de 
Azevedo Mda S, Martins RM, Queirâz DA et al. Epide-
miological features of rotavirus infection in Goiania, 
Goias, Brazil, from 1986 to 2000. Mem Inst Oswaldo 
Cruz 2003;98:25-9.
18. Gomez JA, Sordo ME, Gentile A. Epidemiologic 
patterns of diarrheal disease in Argentina: estima-
tion of rotavirus disease burden. Pediatr Infect Dis J 
2002;21:843-50.
19. González FS, Sordo ME, Rowensztein G, Sabbag L, 
Roussos A, De Petre E et al. Rotavirus diarrhea. Impact 
in a pediatric hospital of Buenos Aires. Medicina (B 
Aires) 1999;59:321-6.
20. Pérez-Schael I, González R, Fernández R, Alfonzo E, 
Inaty D, Boher Y et al. Epidemiological features of ro-
tavirus infection in Caracas, Venezuela: implications 
for rotavirus immunization programs. J Med Virol 
1999;59:520-6.
21. Urrestarazu MI, Liprandi F, Pérez de Suárez E, 
González R, Pérez-Schael I. Etiologic, clinical, and so-
cio-demographic characteristics of acute diarrhea in 
Venezuela. Rev Panam Salud Publica 1999;6:149-56.Constenla DO et al. Economics of rotavirus vaccine in Brazil
JHPN 396
22. Velázquez FR, Matson DO, Guerrero ML, Shults J, 
Calve JJ, Morrow AL et al. Serum antibody as a marker 
of protection against natural rotavirus infection and 
disease. J Infect Dis 2000;182:1602-9.
23. Villa S, Guiscafré H, Martínez H, Muñoz O, Gutiér-
rez G. Seasonal diarrhoeal mortality among Mexican 
children. Bull World Health Organ 1999;77:375-80.  
24. Lopez AD, Salomon J, Ahmad O, Murray CJL, Mafat 
D. Life tables for 191 countries: data, methods and 
results. Geneva: World Health Organization, 2000. 
254 p. (GPE discussion paper no. 9).    
25. Baltussen R, Adam T, Tan Torres T, Hutubessy R, 
Acharya A, Evans D et al. Generalized cost effective- Generalized cost effective-
ness analysis: a guide. Geneva: World Health Organi-
zation, 2002. 329 p.
26. Liddle JL, Burgess MA, Gilbert GL, Hanson RM, Mc-
Intyre PB, Bishop RF et al. Rotavirus gastroenteritis: 
impact on young children, their families, and the 
health care system. Med J Aust 1997;167:304-7.
27. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate 
H, Breuer T, Clemens SC et al. Safety and efficacy of 
an attenuated vaccine against severe rotavirus gastro-
enteritis. N Engl J Med 2006;354:11-22. 
28. Salinas B, Pérez-Schael I, Linhares AC, Ruiz Palacios 
GM, Guerrero ML, Yarzábal JP et al. Evaluation of 
safety, immunogenicity and efficacy of an attenuated 
rotavirus vaccine, RIX4414: a randomized, placebo-
controlled trial in Latin American infants. Ped Infect 
Dis J 2005;24:807-16.
29. World Health Organization. WHO & UNICEF es-
timates of national immunization coverage, 2003. 
10 p. (http://www.who.int/vaccines surveillance/
WHOUNICEF_Coverage Review/, accessed on 11 Oc-
tober 2004).
30. Brenzel L, Claquin P. Immunization programs and 
their costs. Soc Sci Med 1994;39:527-36. 
31. Miller MA, McCann L. Policy analysis of the use of 
hepatitis B, haemophilus influenzae type b-, Strepto-
coccus pneumoniae-conjugate and rotavirus vaccines 
in national immunization schedules. Health Econ 
2004;9:19-35.
32. Walker D, Mosqueira NR, Penny ME, Lanata CF, 
Clark AD, Sanderson CF et al. Variation in the costs 
of delivering routine immunization services in Peru. 
Bull World Health Organ 2004;82:676-82. 
33. Waters HR, Dougherty L, Tegang SP, Tran N, Wi-
ysonge CS, Long K et al. Coverage and costs of child-
hood immunizations in Cameroon. Bull World Health 
Organ 2004;82:668-75. 
34. Constenla D, O’Ryan M, Navarrete MS, Antil L, Rhe-
ingans RD. Potential cost effectiveness of a RV vac-
cine in Chile. Rev Méd Chile 2006;134:679-88.
35. Constenla D, Pérez-Schael I, Rheingans RD, An-
til L, Salas H, Yarzábal JP. Evaluación del impacto 
económico de la vacuna antirrotavírica en Venezuela. 
[Assessment of the economic impact of the antiretro-
viral vaccine in Venezuela]. Rev Panam Salud Pública 
2006;20:213-22 [Spanish].
36. World Health Organization. Macroeconomics and 
health: investing in health for economic develop-
ment: report of the commission on macroeconom-
ics and health. Geneva: World Health Organization, 
2001. 210 p.
37. Sinha A, Levine O, Knoll MD, Muhib F, Lieu TA. Cost-
effectiveness of pneumococcal conjugate vaccination 
in the prevention of child mortality: an international 
economic analysis. Lancet 2007;369:389-96.
38. Constenla D. Evaluating the cost-effectiveness of a 
pneumococcal conjugate vaccination program in 
selected Latin American countries. Rev Panam Salud 
Publica 2008 (in press).
39. Constenla D, Ortega-Barría E, Rheingans R, Antil L, 
Sáez-Llorens X. Impacto económico de la vacuna 
antirrotavirica en Panamá [Economic impact of ro-
tavirus vaccination in Panama]. An Pediat (Barc) 
2008;68:128-35 [Spanish].
40. Constenla D, Rivera M, Rheingans RD, Antil L, 
Vásquez ML. Evaluación económica de una eventual 
incorporación de la vacuna anti-rotavirus en el calen-
dario de vacunación infantil en Honduras. Rev Med 
Hond 2006;74:19-29.
41. Dayan GH, Nguyen VH, Debbag R, Gómez R, Wood 
SC. Cost-effectiveness of influenza vaccination in high-
risk children in Argentina. Vaccine 2001;19:4204-13.